CAS: 2370013-12-8; (R)-N-(5-((4-((5-Chloro-4-Fluoro-2-(2-Hydroxypropan-2-yl)Phenyl)Amino)Pyrimidin-2-yl)Amino)-2-(3-(Dimethylamino)Pyrrolidin-1-yl)-4-Methoxyphenyl)Acrylamide
- 英文名称(R)-N-(5-((4-((5-Chloro-4-Fluoro-2-(2-Hydroxypropan-2-yl)Phenyl)Amino)Pyrimidin-2-yl)Amino)-2-(3-(Dimethylamino)Pyrrolidin-1-yl)-4-Methoxyphenyl)Acrylamide
- 中文名称(R)-N-(5-((4-((5-氯-4-氟-2-(2-羟基丙-2-基)苯基)氨基)嘧啶-2-基)氨基)-2-(3-(二甲氨基)吡咯烷-1-基)-4-甲氧基苯基)丙烯酰胺
- IUPAC名称(R)-N-(5-((4-((5-chloro-4-fluoro-2-(2-hydroxypropan-2-yl)phenyl)amino)pyrimidin-2-yl)amino)-2-(3-(dimethylamino)pyrrolidin-1-yl)-4-methoxyphenyl)acrylamide
- CAS编号2370013-12-8
- MFCD编号:MFCD34567621
- FDA UNII编号:L1Q2K5JYO8
- 分子式:C29H35ClFN7O3分子量:584.1
- 产品CID: 1179450
- 同类组份化合物CAS2370013-49-1 (S-isomer)2370013-12-8 (R-isomer)
- 产品分类JAK/STAT Signaling → EGFR | Protein Tyrosine Kinase/RTK → BTK | JAK/STAT Signaling → EGFR
物理性质
MSDS等安全信息
合成工艺路线路线简述
📜2-氨基-4-氯-5-氟苯甲酸甲酯 在 Potassium Carbonate,氯化铵,N,N-二异丙基乙胺,三氟乙酸,锌体系中,用 四氢呋喃,甲醇,乙醚,水,二甲基亚砜,N,N-二甲基甲酰胺,异丙醇,正丁醇作为反应溶剂,反应 62.25H,获得 (R)-N-(5-((4-((5-Chloro-4-Fluoro-2-(2-Hydroxypropan-2-yl)Phenyl)Amino)Pyrimidin-2-yl)Amino)-2-(3-(Dimethylamino)Pyrrolidin-1-yl)-4-Methoxyphenyl)Acrylamide
参考文献:[En] Erbb/Btk Inhibitors[Fr] Inhibiteurs De Erbb/Btk
标题:[En] Erbb/Btk Inhibitors[Fr] Inhibiteurs De Erbb/Btk
摘要:揭示了抑制erbbs(例如egfr或her 2),特别是erbbs的突变形式,以及btk的化合物,其药用盐,水合物,溶剂合物或立体异构体,以及包含这些化合物的药物组合物.该化合物和药物组合物可以有效治疗erbbs(特别是erbbs的突变形式)或与btk相关的疾病,包括癌症.
海关参考信息
- 2901210000-乙烯
2901220000-丙烯
2902600000-乙苯
2902700000-异丙基苯 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-9174924-B2
优先权日:2007-09-17
标 题 :Hydrolysable linkers and cross-linkers for absorbable polymers
发明人：BEZWADA RAO S
权利人:BEZWADA BIOMEDICAL LLC
摘要:The present invention relates to the discovery of new class of linear and multiarmed hydrolysable linkers and cross linkers for use in the synthesis of biodegradable polymers such as, polyesters, polyurethanes, polyamides, polyureas and degradable epoxy amine resin. The linear and multiarmed hydrolysable linkers of the present invention include symmetrical and/or unsymmetrical ether carboxylic acids, amines, amide diols, amine polyols and isocyanates.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Shi Y, Xu Y, Wang M. Current clinical practice and physicians' insights on Chinese patients with advanced non-small cell lung cancer habouring epidermal growth factor receptor 20 insertion mutation. BMC Cancer. 2024 Aug 23;24(1):1043. doi: 10.1186/s12885-024-12797-3.
2: Ding K, Peng Z, Liu D, Xu Y. Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation. J Transl Med. 2024 Aug 14;22(1):761. doi: 10.1186/s12967-024-05522-y.
3: Luan T, Lin X, Xie X, Yang G, Wang S, Hao J, Zhou C. First case report of sunvozertinib for the treatment of HER2 exon 20 insertion in lung adenocarcinoma. Anticancer Drugs. 2024 Sep 1;35(8):757-760. doi: 10.1097/CAD.0000000000001628. Epub 2024 Jun 26.
合成参考文献
摘要:Kleemann A., Kutscher B., Reichert D., Bossart M., Pharmaceutical Substances, Thieme [Online], Stuttgart, (2026).
📝 需求与反馈
尽可能描述清楚需求与问题信息
